Oramed Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Oramed Pharmaceuticals, Inc. - Product Pipeline Review - 2014" provides data on the Oramed Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Oramed Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Oramed Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Oramed Pharmaceuticals, Inc. - Brief Oramed Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oramed Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oramed Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oramed Pharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oramed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oramed Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oramed Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oramed Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oramed Pharmaceuticals, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Oramed Pharmaceuticals, Inc. Snapshot 4
Oramed Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Oramed Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Oramed Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
Oramed Pharmaceuticals, Inc. - Pipeline Products Glance 10
Oramed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Oramed Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Oramed Pharmaceuticals, Inc. - Drug Profiles 13
ORMD-0801 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
exenatide 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
(exenatide + insulin human) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Oramed Pharmaceuticals, Inc. - Pipeline Analysis 19
Oramed Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 19
Oramed Pharmaceuticals, Inc. - Pipeline Products by Target 20
Oramed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 21
Oramed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 22
Oramed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 23
Oramed Pharmaceuticals, Inc. - Recent Pipeline Updates 24
Oramed Pharmaceuticals, Inc. - Dormant Projects 29
Oramed Pharmaceuticals, Inc. - Company Statement 30
Oramed Pharmaceuticals, Inc. - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Oramed Pharmaceuticals, Inc., Key Information 4
Oramed Pharmaceuticals, Inc., Key Facts 4
Oramed Pharmaceuticals, Inc. - Pipeline by Indication, 2014 6
Oramed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7
Oramed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8
Oramed Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 9
Oramed Pharmaceuticals, Inc. - Phase II, 2014 10
Oramed Pharmaceuticals, Inc. - Phase I, 2014 11
Oramed Pharmaceuticals, Inc. - Preclinical, 2014 12
Oramed Pharmaceuticals, Inc. - Pipeline by Therapeutic Class, 2014 19
Oramed Pharmaceuticals, Inc. - Pipeline by Target, 2014 20
Oramed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 21
Oramed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 22
Oramed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 23
Oramed Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 24
Oramed Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 29
Oramed Pharmaceuticals, Inc., Subsidiaries 32